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A cancer dogma states that inactivation of oncogene(s) can 
cause cancer remission, implying that oncogenes are the Achilles’ 
heel of cancers. This current “hands on” model of cancer has kept 
oncogenes firmly in focus as therapeutic targets and is in agree-
ment with the fact that in human cancers all cancerous cells, with 
independence of the cellular heterogeneity existing within the 
tumor, carry the same oncogenic genetic lesions. This rule has 
now been broken in a study of the effect of the BCR-ABL onco-
gene in cancer development in a mouse model in which oncogene 
expression is restricted to the stem cell compartment. BCR-ABL 
is linked to chronic myeloid leukemia (CML) disease in humans, 
and this study shows that by limiting the oncogene expression 
to Sca1+ cells CML arises, indicating that maintenance of onco-
gene expression is not critical for the generation of differentiated 
tumor cells and showing a “hands off” role for BCR-ABL in 
regulating cancer formation. Here we provide an update on the 
use of this system for modeling human cancer and its potential 
application for therapeutic targeting of cancer stem cells (CSCs) 
and the hands-off function of oncogenes.
Introduction
Since the discovery that human tumors contain activated onco-
genes by the pioneer work of Mariano Barbacid, Geoffrey Cooper, 
Robert Weinberg and Michael Wigler,1-4 many efforts have been 
made to elucidate the causal role that these oncogenes play in 
cancer development. These previous works have shown that onco-
gene expression is not only required for initiation of cancer but also 
for the maintenance of the disease and have kept oncogenes firmly 
in focus as therapeutic targets. In mouse models where oncogene 
expression is driven by tissue-specific promoters, tumors arise at 
high frequency, but disappear again when the inducing stimulus 
is switched off,5-7 suggesting that oncogenes are the Achilles’ heel 
of cancers.8 Overall these observations define an homogenous role 
for oncogenes within cancer cells, as brief inactivation of the single 
tumor-inducing oncogene can cause remission in these model 
systems. These observations are consistent with a “hands on” role 
for oncogenes in regulating tumor formation in a similar way to 
the control of cell-fate determination as a function of lineage-
specific factors.9
This current “hands on” model of cancer is in agreement with 
the fact that in human cancers, all cancerous cells carry the same 
oncogenic genetic lesions. However, it is also a very well-known 
fact that cancers are composed by heterogeneous cell types,10,11 
suggesting that, in the control of oncogenesis, the nature of the 
target cells suffering the effects of oncogenic activity might play an 
important role. In fact, therapy based on the “hands on” model of 
cancer fails to eradicate tumors in humans, as it is well illustrated 
by the BCR-ABL kinase inhibitors such as imatinib/STI571, 
which can target the differentiated tumor cells of chronic myeloid 
leucemia (CML) but fail to eradicate the BCR-ABL-expressing 
stem cells.12,13 On the contrary, these observations are compatible 
with the cancer stem cell (CSC) theory of cancer that suggests 
that tumors are hierarchically organized tissues.14-16 If that was 
indeed the case, then cancer could be created and maintained 
similarly to any other normal stem cell-driven tissue, like the 
hematopoietic system. In a normal stem cell-driven tissue, genetic 
programming of stem cells is all what is required to (re)constitute 
all differentiated cells forming the tissue, and the genetic informa-
tion responsible for the stem cell programming does not need to be 
anymore present within the differentiated cells that form the tissue, 
implying a different function for oncogenes within CSCs. Thus, 
we reasoned that a similar organization could be underlying cancer 
formation. In order to initially address this biological question, we 
have used the BCR-ABLp210 oncogene.17
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Limiting BCR-ABLp210 Expression to Stem Cells Induces 
CML in Mice
A major barrier for the understanding of the contribution 
that CSCs make to the development and maintenance of cancer 
and their suitability as a target was the lack of a system to limit 
 oncogene expression to the CSC compartment. To elucidate if 
cancer is a stem cell-driven tissue, we used the Sca1 locus control 
region to limit oncogene expression to the stem cell compartment 
in a transgenic mouse setting.17 We have initially focused on the 
effects of the BCR-ABLp210 oncogene, linked to chronic myeloid 
leukaemia (CML) in humans.18,19 CML is widely accepted to 
be a stem-cell disorder that begins as a prolonged chronic phase, 
characterized by high leukocyte counts and enlarged spleen and 
liver. In all patients, the chronic phase of CML in the end gives 
rise to a blast crisis that is indistinguishable from acute leukemia. 
The specific BCR-ABL inhibitor STI571 is able to eliminate 
the BCR-ABL-expressing differentiated cells that constitute the 
bulk of the tumor, but it cannot eliminate BCR-ABL-expressing 
CSCs.12,13
When the expression of BCR-ABL is restricted to the Sca1+ 
cells in mice, these Sca1-BCR-ABLp210 mice fully develop CML. 
In these Sca1-BCR-ABLp210 mice, although initiation takes 
place within the stem cell/progenitor population, the oncogene 
is switched off in the tumor differentiated cells which constitute 
the bulk of the tumor. In the paper by Perez-Caro et al.17 quan-
titative RT-PCR analysis of BCR-ABL transcripts was used to 
define patterns of BCR-ABL gene expression in pure populations 
of hematopoietic cells. Overall, BCR-ABL is not expressed in 
lineage-positive hematopoietic progenitors, but it could be that 
BCR-ABL target genes could continue to be expressed in the 
absence of BCR-ABL. These genes could be targets of a “hit 
and run” mode of action in which BCR-ABL turns genes on in 
stem cells but is not required for maintaining their expression at 
later stages of development. However, neither BCR-ABL protein 
nor downstream signaling were detected in Sca1-Lin+ cells of 
Sca1-BCR-ABLp210 mice. The data support the hypothesis that 
BCR-ABL downstream targets are switched off after the silencing 
of BCR-ABL. It might appear then counter-intuitive and surprising 
that cancers develop efficiently in these mice since in actual human 
cancers all cancerous cells carry the oncogenic genetic lesions, not 
only the cancer stem cells. Nevertheless, CML arises in these mice 
indicating that silencing of BCR-ABL is not critical for generation 
of differentiated tumor cells and suggesting a “hands off ” role for 
BCR-ABL in regulating tumor formation (Fig. 1).
To determine whether the continuous presence of BCR-ABL is 
necessary for the maintenance of CSCs we treated diseased Sca1-
BCR-ABLp210 mice with the specific BCR-ABL inhibitor STI571 
and we found that the course of the CML disease was not modified 
upon treatment. These observations demonstrate that blocking 
BCR-ABL function (or at least abolishing its tyrosine-kinase 
activity) is not efficient in eliminating the CSCs, in agreement 
with both of the above-mentioned observations showing that 
STI571 treatment fails to eradicate the BCR-ABL-expressing stem 
cells in human patients12,13 and the development of CML in our 
BCR-ABL “hands-off ” model (Fig. 1).
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Figure 1. A “hands off” role for BCR-ABL in regulating CML formation. (A) Adopting a lineage amongst two or more options is a fundamental devel-
opmental decision in multicellular organisms. The control of cell-fate determination of a stem cell is a function of the balance between lineage-specific 
factors. (B) In our stem cell-driven cancer model, the expression of the oncogenic alteration is restricted to the progenitor compartment but is neverthe-
less capable of generating a full-blown tumor with all its differentiated cellular components, showing a hands-off role for BCR-ABL in regulating CML 
formation. This model implicitly relies in the fact that the oncogenic presence in the CSC compartment originates (epi)genetic latent alterations which 
are responsible for the posterior appearance of the tumoral phenotype.17 Consistent with this, forced expression of these genes can—in certain cellular 
environments—select or impose a lineage outcome, explaining why most chimeric oncogenes created after chromosomal translocations are found only 
in one type of tumor.
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just reflect the function of the oncogene at the stem cell level.
One possible hypothesis would be that the BCR-ABL oncogene 
activity might be promoting the aging of the targeted stem cells. 
In this regard, it has been described by expression profiling tools 
that HSC aging is accompanied by the downregulation of genes 
mediating lymphoid specification and function and upregulation 
of genes involved in specifying myeloid fate and function.20 Thus 
we next examined the expression of genes associated to physi-
ological HSC aging20 in CSCs from Sca1-BCR-ABLp210 mice. 
A shown in Figure 2, CSCs from Sca1-BCR-ABLp210 mice share 
several features with aged stem cells. These data support a model in 
which stem cells may be affected in similar ways by aging and by 
oncogenes. As young stem cells are more resistant to chemotherapy 
than aged stem cells, these findings suggest a therapeutic window 
opportunity to destroy the CSCs while keeping intact the normal 
stem cell compartment.
A “Hands Off” Role for BCR-ABL in Regulating Tumor 
Formation
In human pathologies and in most animals models of cancer, 
the oncogenic alteration(s) is(are) present in all the cellular types 
that compose the tumoral tissue, from the cancer stem cells to the 
more differentiated types. In our stem cell-driven cancer model, 
the expression of the oncogenic alteration is restricted to the 
progenitor compartment but is nevertheless capable of generating 
a full-blown tumor with all its differentiated cellular components, 
showing a hands-off role for BCR-ABL in regulating CML forma-
tion. Of course, this model implies that the oncogenic activity 
in the cancer stem cell compartment causes (epi)genetic latent 
But because we wanted to address the question of whether 
CSCs are required continuously for maintenance of the CML 
disease, we used a model in which Sca1+, BCR-ABL-expressing 
cells are deleted in the presence of gancyclovir. After elimination of 
the CSC, we were able to eradicate the whole tumor. These obser-
vations formally prove that CSCs are required continuously for 
maintenance of the CML disease. However, abolishing BCR-ABL 
function is not critical for the generation of differentiated tumor 
cells. In our view, this constitutes the most convincing evidence 
to date that these cancers arise and are driven by a cell fate change 
within the stem cells, and that this population is the ultimate target 
for cancer therapy. In total, the data suggest a “hands off ” role for 
BCR-ABL in regulating cancer formation.
How Does BCR-ABL Program Stem Cells to Make a CML?
In order to identify the genes that are associated with 
BCR-ABLp210-induced reprogramming of stem cells we 
performed a supervised analysis of the transcriptional profiles 
of CSCs purified from Sca1-BCR-ABLp210 mice versus HSCs 
from control mice. The data identified a set of genes that are 
reproducibly differentially regulated in CSCs versus control stem 
cells. Because the CSC hypothesis could imply that cancer results 
from the activation of dormant embryonal-rest cells,10,11 we next 
proceeded to examine, in CSCs from Sca1-BCR-ABLp210 mice, 
the expression of embryonic surface markers that have been previ-
ously identified in undifferentiated mouse embryonic stem cells 
and we could show that CSCs in Sca1-BCR-ABLp210 mice present 
embryonic figures.17 Although overall these observations identify 
potential attractive targets for selective CSC removal, they may also 
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Figure 2. Cancer stem cells in Sca1-BCR-ABLp210 mice share features with aged stem cells. To identify genes associated with BCR-ABLp210-induced 
reprogramming of stem cells, we have compared the gene expression profiles of purified CSC populations versus normal HSCs. Both CSCs and HSCs 
were isolated as Sca1+Lin- cells. The figure represents a graphical description of the patterns of expression, in CSCs from Sca1-BCR-ABLp210 mice, of 
lymphoid (A) or myeloid (B) genes previously identified as being differentially regulated in old HSCs.20 Genes were selected for which signal intensities 
were changed ± 2 in CSCs vs. HSCs. We referred the ratios of the CSCs to the control hematopoietic stem cells (Sca1+Lin- cells purified from control 
mice). Each gene (identified at right) is represented by a single row of colored boxes; each experimental mouse is represented by a single column. Data 
are displayed by a color code. Red fields indicate higher values than the median, green fields indicate lower values than the median. The colour bar 
on the right site of each panel indicates genes upregulated (red) or downregulated (green) in aged HSCs.20
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mice develop additional solid tumors. Considering that Sca1 has 
been identified as a almost universal stem cell marker in many 
different tissues, these data suggest that stem cell-driven oncogen-
esis is not specific to only hematopietic tissues, but rather represents 
a broader mechanism for deregulation of stem cell differentiation, 
providing a paradigm that can be applied to solid-organ cancers. 
Thus, it is to be expected that CSCs from different cancer types 
will share many similarities, implying that similar CSC-based 
therapeutic approaches could be used in many different cancers. 
The challenge is now to find a way to specifically target CSCs and/
or the hands-off oncogenic regulation mechanism without causing 
toxicity to normal cells.
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alterations which are responsible for the later appearance of the 
tumoral phenotype.17 In fact, our initial characterization of CSCs 
has shown that BCR-ABL causes secondary genetic or epigenetic 
changes (such as DNA methylation, centrosome abnormalities 
and consequent aneuploidy, and others) which may be inherited 
by subsequent generations regardless of the lack of continued 
BCR-ABL expression. Thus, BCR-ABL oncogene inactivation 
cannot change this epigenetic/genetic context at the CSC level, 
in agreement with the common occurrence of tumor relapse by 
which human CML evolves to escape BCR-ABL pharmacological 
inactivation. Moreover, these results show that the control of 
oncogenesis is a function of both the target-cell and the genetic 
oncogenic alteration(s), being the molecular mechanisms of action 
of BCR-ABLp210 at the CSC level different from those acting at 
later stages of tumoral cell differentiation.
Conclusions and Future Directions
Despite a better understanding of the biology of tumor cells, 
the treatment of most cancers has no significantly changed for 
the past four decades and the decreasing mortality has been 
mostly the result of early detection and prevention rather than 
the consequence of effective therapeutics.21-23 Thus, the cells and 
genetic lesions responsible for maintaining the disease remain an 
intriguing and exciting topic of research, since these cells have been 
posited to be responsible for resistance to conventional therapies, 
recurrence and metastasis.24
We have shown that cancer growth and elimination was 
achieved by targeting oncogene expression to the CSCs only.17 
Thus, if the growth potential of a cancer depends on CSCs and 
on oncogenes that can function in a hands-off manner, it seems 
important to know how to eradicate these cells and/or inactivate 
the hands-off mechanism. Similarly, assessing the ability of any 
candidate therapy to destroy these cells would seem crucial to 
predicting its efficacy.25 The evidence for the existence of CSCs in 
human tumors is based on the creation of mice that are sufficiently 
immunodeficient to tolerate the growth of primary human cells 
into them.25 However, this growth does not exclude the possibility 
that engraftment rather than cancer stem cell activity correlates 
with a particular phenotype.26 CSC-based models, as the one 
described in Perez-Caro et al.17 allow bypassing the limitations 
and experimental variability of the xenotransplant models. An 
enormous advantage of our CSC-based models is that they not 
only enable syngeneic transplantation but they also allow studying 
the disease at its early stages in order to analyse the changes in 
CSCs long before the cancer can be phenotypically (=clinically) 
detected.
Besides the therapy per se, an essential element in cancer 
management is the evaluation of treatment efficacy. Therefore, 
new clinical methodologies need to be developed to evaluate the 
efficacy of CSC-based therapies and here again the CSC-based 
models will be pivotal to achieve this aim.
But perhaps the most crucial question of all is whether hands-
off regulation mechanisms can be found in other cancer types, 
especially tumors of epithelial origin, which represent the bulk of 
human cancers. Importantly, a small subset of Sca1-BCR-ABLp210 
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